Education
About Us
Working with TipRanks
Follow Us
Dyadic International Inc. (DYAI)
:DYAI
DYAI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.71 - $2.20
Previous CloseN/A
Volume131.09K
Average Volume (3M)206.66K
Market Cap
$32.74M
Enterprise Value$28.29M
Total Cash (Recent Filing)$6.57M
Total Debt (Recent Filing)$5.06M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Nov 05, 2025EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding36,187,798
10 Day Avg. Volume151,263
30 Day Avg. Volume206,664
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.86
Enterprise Value/Revenue6.84
Enterprise Value/Gross Profit9.09
Enterprise Value/Ebitda-5.41
Forecast
1Y Price Target
$6.00Price Target Upside545.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Dyadic International News
DYAI FAQ
What was Dyadic International Inc.’s price range in the past 12 months?
Dyadic International Inc. lowest stock price was $0.71 and its highest was $2.20 in the past 12 months.
What is Dyadic International Inc.’s market cap?
Dyadic International Inc.’s market cap is $32.74M.
When is Dyadic International Inc.’s upcoming earnings report date?
Dyadic International Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 68 days.
How were Dyadic International Inc.’s earnings last quarter?
Dyadic International Inc. released its earnings results on Aug 13, 2025. The company reported -$0.06 earnings per share for the quarter, the consensus estimate of -$0.06 by $0.
Is Dyadic International Inc. overvalued?
According to Wall Street analysts Dyadic International Inc.’s price is currently Undervalued.
Does Dyadic International Inc. pay dividends?
Dyadic International Inc. does not currently pay dividends.
What is Dyadic International Inc.’s EPS estimate?
Dyadic International Inc.’s EPS estimate is -0.03.
How many shares outstanding does Dyadic International Inc. have?
Dyadic International Inc. has 36,187,798 shares outstanding.
What happened to Dyadic International Inc.’s price movement after its last earnings report?
Dyadic International Inc. reported an EPS of -$0.06 in its last earnings report, expectations of -$0.06. Following the earnings report the stock price went down -2.439%.
Which hedge fund is a major shareholder of Dyadic International Inc.?
Currently, no hedge funds are holding shares in DYAI
Dyadic International Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (545.16% Upside)
$6.00 (545.16% Upside)
Hedge Fund Trend
Decreased
By 183.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $24.7K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.30%
12-Months-Change
Fundamentals
Return on Equity
-422.64%
Trailing 12-Months
Asset Growth
-23.45%
Trailing 12-Months
Company Description
Dyadic International Inc.
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
DYAI Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed a positive outlook with significant revenue growth, strategic rebranding, strong partnerships, and financial positioning to support future product launches. However, the company still faces challenges with a notable net loss and uncertain cash burn rate.View all DYAI earnings summariesTechnical Analysis
Clearside Biomedical
―
Collplant Holdings
―
Reviva Pharmaceuticals Holdings
―
Generation Bio
―
Rani Therapeutics Holdings
―
Ownership Overview
15.73% Insiders
2.91% Mutual Funds
7.84% Other Institutional Investors
71.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---